Breakthrough T1D

Supports biomedical innovation in the United States through a charitable mission focused on type one diabetes.

Breakthrough T1D is the US nonprofit formerly known as JDRF. Founded in 1970 and rebranded in June 2024, it is a 501(c)(3) based in New York that funds research to cure, prevent, and treat type 1 diabetes and its complications. The organization estimates that 1.5 million Americans and 9.5 million people globally live with T1D.

The organization backs academic and industry partners through Strategic Research Agreements, training awards, topic-specific research RFAs, conference support, and an industry discovery and development partnership for for-profit organizations. Its training awards run on a July 2, 2026 deadline, while the master index also points to project-concept cycles for SRA and a set of live topic calls spanning cardiovascular disease, insulin dose, ketones, immune tolerance, vascularization, and diabetes-on-a-chip work.

Breakthrough T1D does not run its own laboratories. It works through milestone-driven research partnerships, quarterly reporting, and direct contact with its scientists, while its international affiliates in the UK, Australia, Canada, Israel, and the Netherlands operate as separate legal entities.